Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Montani, B. Girerd, F. Coulet, B. Sztrymf, A. Yaici, X. Jaïs, A. Reis, V. Drouin-Garraud, A. Fraisse, O. Sitbon, G. Simonneau, F. Soubrier, M. Humbert (Clamart, France). Clinical outcomes of pulmonary arterial hypertension in carriers of ACVRL1 (ALK1) mutation. Eur Respir J 2009; 34: Suppl. 53, 169

Member's Comments

No comment yet.

Related content which might interest you: Patients‘, relatives‘ and practitioners‘ views on pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Cure pulmonary arterial hypertension associated with HIV (PAH-HIV)? … Toward an answer Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Clinical presentation, hemodynamical characteristics and survival of patients with pulmonary arterial hypertension carrying or not a BMPR2 mutation Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Late Breaking Abstract: Pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF) in early course of disease – A prospective evaluation with right heart catheterization (RHC) in the ARTEMIS-IPF study Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 HbA1c in pulmonary arterial hypertension – A marker of prognostic relevance? Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Survival in pulmonary hypertension in Spain: insights from the Spanish registry}, Source: Eur Respir J 2012; 40: 596-603 Year: 2012 Usefulness of differential blood gas exchange assessment in patients with severe pulmonary arterial hypertension (PAH) associated to congenital heart disease (CHD) Source: Eur Respir J 2005; 26: Suppl. 49, 351s Year: 2005 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Clinical characteristics, hemodynamics and survival in idiopathic and familial pulmonary arterial hypertension with germline BMPR2 mutation Source: Eur Respir J 2007; 30: Suppl. 51, 250s Year: 2007 Predicting survival in pulmonary arterial hypertension in the UK}, Source: Eur Respir J 2012; 40: 604-611 Year: 2012 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016